Carmella Evans-Molina1,2,3,4,5,6, Emily K Sims4,5, Linda A DiMeglio4,5, Heba M Ismail7, Andrea K Steck8, Jerry P Palmer9, Jeffrey P Krischer10, Susan Geyer10, Ping Xu10, Jay M Sosenko11. 1. Departments of Medicine. 2. Cellular and Integrative Physiology. 3. Biochemistry and Molecular Biology. 4. Pediatrics, and the. 5. Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA. 6. Roudebush VA Medical Center, Indianapolis, Indiana, USA. 7. Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 8. Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Denver, Colorado, USA. 9. VA Puget Sound Health Care System and the University of Washington, Seattle, Washington, USA. 10. Health Informatics Institute, University of South Florida, Tampa, Florida, USA. 11. Department of Medicine and the Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, Florida, USA.
Abstract
BACKGROUND: The duration and patterns of β cell dysfunction during type 1 diabetes (T1D) development have not been fully defined. METHODS: Metabolic measures derived from oral glucose tolerance tests (OGTTs) were compared between autoantibody-positive (aAb+) individuals followed in the TrialNet Pathway to Prevention study who developed diabetes after 5 or more years or less than 5 years of longitudinal follow-up (Progressors≥5, n = 75; Progressors<5, n = 474) and 144 aAb-negative (aAb-) relatives. RESULTS: Mean age at study entry was 15.0 ± 12.6 years for Progressors≥5; 12.0 ± 9.1 for Progressors<5; and 16.3 ± 10.4 for aAb- relatives. At baseline, Progressors≥5 already exhibited significantly lower fasting C-peptide (P < 0.01), C-peptide AUC (P < 0.001), and early C-peptide responses (30- to 0-minute C-peptide; P < 0.001) compared with aAb- relatives, while 2-hour glucose (P = 0.03), glucose AUC (<0.001), and Index60 (<0.001) were all higher. Despite significant baseline impairment, metabolic measures in Progressors≥5 were relatively stable until 2 years prior to T1D diagnosis, when there was accelerated C-peptide decline and rising glycemia from 2 years until diabetes diagnosis. Remarkably, patterns of progression within 3 years of diagnosis were nearly identical between Progressors≥5 and Progressors<5. CONCLUSION: These data provide insight into the chronicity of β cell dysfunction in T1D and indicate that β cell dysfunction may precede diabetes diagnosis by more than 5 years in a subset of aAb+ individuals. Even among individuals with varying lengths of aAb positivity, our findings indicate that patterns of metabolic decline are uniform within the last 3 years of progression to T1D. TRIAL REGISTRATION: Clinicaltrials.gov NCT00097292. FUNDING: The Type 1 Diabetes TrialNet Study Group is a clinical trials network currently funded by the NIH through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Juvenile Diabetes Research Foundation.
BACKGROUND: The duration and patterns of β cell dysfunction during type 1 diabetes (T1D) development have not been fully defined. METHODS: Metabolic measures derived from oral glucose tolerance tests (OGTTs) were compared between autoantibody-positive (aAb+) individuals followed in the TrialNet Pathway to Prevention study who developed diabetes after 5 or more years or less than 5 years of longitudinal follow-up (Progressors≥5, n = 75; Progressors<5, n = 474) and 144 aAb-negative (aAb-) relatives. RESULTS: Mean age at study entry was 15.0 ± 12.6 years for Progressors≥5; 12.0 ± 9.1 for Progressors<5; and 16.3 ± 10.4 for aAb- relatives. At baseline, Progressors≥5 already exhibited significantly lower fasting C-peptide (P < 0.01), C-peptide AUC (P < 0.001), and early C-peptide responses (30- to 0-minute C-peptide; P < 0.001) compared with aAb- relatives, while 2-hour glucose (P = 0.03), glucose AUC (<0.001), and Index60 (<0.001) were all higher. Despite significant baseline impairment, metabolic measures in Progressors≥5 were relatively stable until 2 years prior to T1D diagnosis, when there was accelerated C-peptide decline and rising glycemia from 2 years until diabetes diagnosis. Remarkably, patterns of progression within 3 years of diagnosis were nearly identical between Progressors≥5 and Progressors<5. CONCLUSION: These data provide insight into the chronicity of β cell dysfunction in T1D and indicate that β cell dysfunction may precede diabetes diagnosis by more than 5 years in a subset of aAb+ individuals. Even among individuals with varying lengths of aAb positivity, our findings indicate that patterns of metabolic decline are uniform within the last 3 years of progression to T1D. TRIAL REGISTRATION: Clinicaltrials.gov NCT00097292. FUNDING: The Type 1 Diabetes TrialNet Study Group is a clinical trials network currently funded by the NIH through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Juvenile Diabetes Research Foundation.
Authors: Jay S Skyler; Carla J Greenbaum; John M Lachin; Ellen Leschek; Lisa Rafkin-Mervis; Peter Savage; Lisa Spain Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691
Authors: Katarzyna Siewko; Anna Popławska-Kita; Beata Telejko; Rafał Maciulewski; Anna Zielińska; Agnieszka Nikołajuk; Maria Górska; Małgorzata Szelachowska Journal: Endokrynol Pol Date: 2014 Impact factor: 1.582
Authors: Kendra Vehik; Craig A Beam; Jeffrey L Mahon; Desmond A Schatz; Michael J Haller; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer Journal: Diabetes Care Date: 2011-07-12 Impact factor: 19.112
Authors: Maria J Redondo; Jesse Muniz; Luisa M Rodriguez; Dinakar Iyer; Fariba Vaziri-Sani; Morey W Haymond; Christiane S Hampe; Michael L Metzker; Struan F A Grant; Ashok Balasubramanyam Journal: BMJ Open Diabetes Res Care Date: 2014-04-06
Authors: Craig Dorrell; Jonathan Schug; Pamela S Canaday; Holger A Russ; Branden D Tarlow; Maria T Grompe; Tamara Horton; Matthias Hebrok; Philip R Streeter; Klaus H Kaestner; Markus Grompe Journal: Nat Commun Date: 2016-07-11 Impact factor: 14.919
Authors: Jay M Sosenko; Jerry P Palmer; Lisa E Rafkin; Jeffrey P Krischer; David Cuthbertson; Carla J Greenbaum; George Eisenbarth; Jay S Skyler Journal: Diabetes Care Date: 2009-12-23 Impact factor: 17.152
Authors: Martha Campbell-Thompson; Ann Fu; John S Kaddis; Clive Wasserfall; Desmond A Schatz; Alberto Pugliese; Mark A Atkinson Journal: Diabetes Date: 2015-11-18 Impact factor: 9.461
Authors: Pia Leete; Roberto Mallone; Sarah J Richardson; Jay M Sosenko; Maria J Redondo; Carmella Evans-Molina Journal: Curr Diab Rep Date: 2018-09-26 Impact factor: 4.810
Authors: Melanie R Shapiro; Clive H Wasserfall; Sean M McGrail; Amanda L Posgai; Rhonda Bacher; Andrew Muir; Michael J Haller; Desmond A Schatz; Johnna D Wesley; Matthias von Herrath; William A Hagopian; Cate Speake; Mark A Atkinson; Todd M Brusko Journal: Diabetes Date: 2019-12-11 Impact factor: 9.461
Authors: Maria J Redondo; Jay Sosenko; Ingrid Libman; Jennifer J F McVean; Mustafa Tosur; Mark A Atkinson; Dorothy Becker; Susan Geyer Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958
Authors: Emily K Sims; Brian N Bundy; Kenneth Stier; Elisavet Serti; Noha Lim; S Alice Long; Susan M Geyer; Antoinette Moran; Carla J Greenbaum; Carmella Evans-Molina; Kevan C Herold Journal: Sci Transl Med Date: 2021-03-03 Impact factor: 17.956